Article
Association between ABCG2 and SLCO1B1 polymorphisms and adverse drug reactions to regorafenib: a preliminary study .
International journal of clinical pharmacology and therapeutics - 1 May 2017
Maeda Akimitsu, Ando Hitoshi, Ura Takashi, Komori Azusa, Hasegawa Ayako, Taniguchi Hiroya, Kadowaki Shigenori, Muro Kei, Tajika Masahiro, Kobara Makiko, Matsuzaki Masahide, Hashimoto Naoya, Maeda Mieko, Kojima Yasushi, Aoki Masahiro, Kondo Eisaku, Mizutani Akiyoshi, Fujimura Akio
Abstract excerpt
OBJECTIVE: Due to the occurrence of severe adverse drug reactions to regorafenib, a drug used in cancer therapy, the identification of a predictive marker(s) is needed to increase the therapeutic applicability of this compound. We therefore investigated whether polymorphisms in the ABCG2 and SLCO1B genes are associated with adverse drug reactions to regorafenib. METHODS: For these analyses, 37 Japanese cancer...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.